Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma

- Carlino, Matteo S., Gowrishankar, Kavitha, Rizos, Helen, Saunders, Catherine A. B., Pupo, Gulietta M., Snoyman, Stephanie, Zhang, Xu Dong, Saw, Robyn, Becker, Therese M., Kefford, Richard F., Long, Georgina V.

Metastatic acral melanoma treatment outcomes: A systematic review and meta-analysis

- Cho, Kenneth K., Cust, Anne E., Foo, Yun Megan, Long, Georgina V., Menzies, Alexander M., Eslick, Guy D.

Pharmacodynamic effects and mechanisms of resistance to Vemurafenib in patients with metastatic melanoma

- Trunzer, Kerstin, Pavlick, Anna C., Hersey, Peter, Long, Georgina V., Lawrence, Donald, Ott, Patrick A., Amaravadi, Ravi K., Lewis, Karl D., Puzanov, Igor, Lo, Roger S., Koehler, Astrid, Kockx, Mark, Schuchter, Lynn, Spleiss, Olivia, Schell-Steven, Annette, Gilbert, Houston N., Cockey, Louise, Bollag, Gideon, Lee, Richard J., Joe, Andrew K., Sosman, Jeffrey A., Ribas, Antoni, Gonzalez, Rene, McArthur, Grant A., Hutson, Thomas E., Moschos, Stergios J., Flaherty, Keith T., Kim, Kevin B., Weber, Jeffrey S.

TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells

- Sutton, Selina K., Koach, Jessica, Long, Georgina V., Liu, Tao, McArthur, Grant, Zhang, Xu Dong, Scolyer, Richard A., Cheung, Belamy B., Marshall, Glenn M., Tan, Owen, Liu, Bing, Carter, Daniel R., Wilmott, James S., Yosufi, Benafsha, Haydu, Lauren E., Mann, Graham J., Thompson, John F.